Showing 1 to 3 of 3 results


HIMS Earnings Announcement: 47% Chance of Positive One-Day Return
Hims & Hers Health (HIMS) reports earnings on August 4, 2025; historical data shows a 47% chance of positive one-day returns post-earnings, with analysts projecting substantial revenue growth compared to last year.
HIMS Earnings Announcement: 47% Chance of Positive One-Day Return
Hims & Hers Health (HIMS) reports earnings on August 4, 2025; historical data shows a 47% chance of positive one-day returns post-earnings, with analysts projecting substantial revenue growth compared to last year.
Progress
36% Bias Score


HIMS Stock Rises Despite Volatility, Driven by Diverse Revenue Streams
Hims & Hers Health (HIMS) stock price rose from $23.50 in July to $32.50 currently, despite September's dip below $14; its compounded semaglutide injections, representing under 10% of revenue, contribute to volatility, while the company shows continued strength.
HIMS Stock Rises Despite Volatility, Driven by Diverse Revenue Streams
Hims & Hers Health (HIMS) stock price rose from $23.50 in July to $32.50 currently, despite September's dip below $14; its compounded semaglutide injections, representing under 10% of revenue, contribute to volatility, while the company shows continued strength.
Progress
40% Bias Score

FDA Warns of Serious Side Effects from Online Topical Finasteride
The FDA warned about serious side effects, including sexual dysfunction and suicidal ideation, from unapproved topical finasteride hair-loss treatments sold online by telehealth companies like Hims, Hers, and Ro, with 32 complaints filed between 2019 and 2024.

FDA Warns of Serious Side Effects from Online Topical Finasteride
The FDA warned about serious side effects, including sexual dysfunction and suicidal ideation, from unapproved topical finasteride hair-loss treatments sold online by telehealth companies like Hims, Hers, and Ro, with 32 complaints filed between 2019 and 2024.
Progress
64% Bias Score
Showing 1 to 3 of 3 results